Related references
Note: Only part of the references are listed.Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes
Jasmin Federizon et al.
VACCINE (2020)
An Engineered Biomimetic MPER Peptide Vaccine Induces Weakly HIV Neutralizing Antibodies in Mice
Shuai Shao et al.
ANNALS OF BIOMEDICAL ENGINEERING (2020)
Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment
Wei-Chiao Huang et al.
NPJ VACCINES (2020)
Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo
Yang Yang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy
Min Luo et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication
Sean K. Maynard et al.
BMC CANCER (2019)
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines
Giuseppe Del Giudice et al.
SEMINARS IN IMMUNOLOGY (2018)
Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice
Gabriele Galliverti et al.
CANCER IMMUNOLOGY RESEARCH (2018)
A malaria vaccine adjuvant based on recombinant antigen binding to liposomes
Wei-Chiao Huang et al.
NATURE NANOTECHNOLOGY (2018)
Peptide Delivery Systems for Cancer Vaccines
Xuedan He et al.
ADVANCED THERAPEUTICS (2018)
Adjuvant system AS01: helping to overcome the challenges of modern vaccines
Arnaud M. Didierlaurent et al.
EXPERT REVIEW OF VACCINES (2017)
A STING-activating nanovaccine for cancer immunotherapy
Min Luo et al.
NATURE NANOTECHNOLOGY (2017)
Control of immune escaped human papilloma virus is regained after therapeutic vaccination
Wenbo Ma et al.
CURRENT OPINION IN VIROLOGY (2017)
Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines
Eleni Maria Varypataki et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Gapped sequence alignment using artificial neural networks: application to the MHC class I system
Massimo Andreatta et al.
BIOINFORMATICS (2016)
HPV16 variants distribution in invasive cancers of the cervix, vulva, vagina, penis, and anus
Sara Nicolas-Parraga et al.
CANCER MEDICINE (2016)
Adjuvants for peptide-based cancer vaccines
Hiep Khong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Vaccines for established cancer: overcoming the challenges posed by immune evasion
Sjoerd H. van der Burg et al.
NATURE REVIEWS CANCER (2016)
Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation
Sima Rahimian et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens
Shuai Shao et al.
NATURE CHEMISTRY (2015)
Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination
Benjamin Yang et al.
CELL AND BIOSCIENCE (2015)
Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients
Kei Kawana et al.
VACCINE (2014)
Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients
Tae Jin Kim et al.
NATURE COMMUNICATIONS (2014)
Understanding the biology of antigen cross-presentation for the design of vaccines against cancer
Cynthia M. Fehres et al.
FRONTIERS IN IMMUNOLOGY (2014)
BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses
Hyun-Il Cho et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Presentation of Phagocytosed Antigens by MHC Class I and II
Adriana R. Mantegazza et al.
TRAFFIC (2013)
TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers
Kelly Barrios et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Preventing Cancer with Vaccines: Progress in the Global Control of Cancer
Mark A. Kane
CANCER PREVENTION RESEARCH (2012)
Targeting tumor antigens to dendritic cells using particulate carriers
Medha D. Joshi et al.
JOURNAL OF CONTROLLED RELEASE (2012)
A novel self-assembled nanoparticle vaccine with HIV-1 Tat49-57/HPV16 E749-57 fusion peptide and GM-CSF DNA elicits potent and prolonged CD8+ T cell-dependent anti-tumor immunity in mice
Jun Tang et al.
VACCINE (2012)
Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients
W. Joost Lesterhuis et al.
CLINICAL CANCER RESEARCH (2011)
Recombinant HPV16 E7 assembled into particles induces an immune response and specific tumour protection administered without adjuvant in an animal model
Linda Petrone et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice
Milaid Granadillo et al.
VACCINE (2011)
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses
Marij J. P. Welters et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Carrageenan as an adjuvant to enhance peptide-based vaccine potency
Yu-Qian Zhang et al.
VACCINE (2010)
Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation
Chao-Yi Wu et al.
JOURNAL OF BIOMEDICAL SCIENCE (2010)
Human papillomavirus oncoproteins: pathways to transformation
Cary A. Moody et al.
NATURE REVIEWS CANCER (2010)
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia.
Gemma G. Kenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix
Paulo Cesar Maciag et al.
VACCINE (2009)
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows lowtoxicity and robust immunogenicity
Gemma G. Kenter et al.
CLINICAL CANCER RESEARCH (2008)
Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine
Weihsu Chen et al.
MOLECULAR PHARMACEUTICS (2008)
Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: A phase I escalating-dose trial
Alessandro D. Santin et al.
JOURNAL OF VIROLOGY (2008)
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT
James N. Kochenderfer et al.
BLOOD (2007)
Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant:: therapeutic activity against human cervical cancer in a rodent model
Zhengrong Cui et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Vaccination with human papillomavirus type 16 E7 peptide with CpG oligonucleotides for prevention of tumor growth in mice
KB Gendron et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2006)
Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors
I Torréns et al.
VACCINE (2005)
Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model
A Vambutas et al.
VACCINE (2005)
Reliable prediction of T-cell epitopes using neural networks with novel sequence representations
M Nielsen et al.
PROTEIN SCIENCE (2003)
Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine
A de Jong et al.
VACCINE (2002)
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
L Alexopoulou et al.
NATURE (2001)
Share Paper
